Novartis Ag

Nafeeza Hafeez

Pascal Furet

Robin Alec Fairhurst

Robert Mah

Bo Han

Matthew J LaMarche

Catherine Leblanc

Can Wang

Jorge Garcia Fortanet

Lv Liao

Jing Xiong

Nicole Buschmann

Dale Porter

Diana Graus Porta

Markus Wartmann

Xianglin Zhao

Thomas Knoepfel

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations

Growing community of inventors

Brookline, MA, United States of America

Nafeeza Hafeez